These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 33411965

  • 1. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X, Real FX, Malats N, Ye W.
    Int J Cancer; 2021 Apr 15; 148(8):2048-2058. PubMed ID: 33411965
    [Abstract] [Full Text] [Related]

  • 2. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.
    J Natl Cancer Inst; 2017 Apr 01; 109(4):. PubMed ID: 28376157
    [Abstract] [Full Text] [Related]

  • 3. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L.
    Cancer Sci; 2018 Sep 01; 109(9):2841-2851. PubMed ID: 29945294
    [Abstract] [Full Text] [Related]

  • 4. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S.
    Cancer Prev Res (Phila); 2021 Jul 01; 14(7):729-740. PubMed ID: 33893071
    [Abstract] [Full Text] [Related]

  • 5. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T.
    PLoS Med; 2020 Dec 01; 17(12):e1003489. PubMed ID: 33301466
    [Abstract] [Full Text] [Related]

  • 6. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376184
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y.
    Int J Cancer; 2014 Jun 01; 134(11):2646-55. PubMed ID: 24615168
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.
    BMC Cancer; 2013 Sep 03; 13():404. PubMed ID: 24007603
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
    Lindgaard SC, Sztupinszki Z, Maag E, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Hansen CP, Hasselby JP, Nielsen KR, Szallasi Z, Johansen JS.
    Clin Cancer Res; 2021 May 01; 27(9):2592-2603. PubMed ID: 33737308
    [Abstract] [Full Text] [Related]

  • 13. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA, Durbin-Johnson B, Urayama S.
    J Gastrointest Cancer; 2014 Mar 01; 45(1):74-9. PubMed ID: 24272911
    [Abstract] [Full Text] [Related]

  • 14. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection.
    Ney A, Nené NR, Sedlak E, Acedo P, Blyuss O, Whitwell HJ, Costello E, Gentry-Maharaj A, Williams NR, Menon U, Fusai GK, Zaikin A, Pereira SP.
    PLoS Comput Biol; 2024 Aug 01; 20(8):e1012408. PubMed ID: 39208354
    [Abstract] [Full Text] [Related]

  • 15. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, Qian L, Zhao J, Zong H, Kang B, Zou WB, Chen K, He X, Meng Z, Chen Z, Huang S, Wang P.
    Gut; 2020 Mar 01; 69(3):540-550. PubMed ID: 31562239
    [Abstract] [Full Text] [Related]

  • 16. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
    Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y.
    J Cancer Res Clin Oncol; 2013 Jul 01; 139(7):1117-27. PubMed ID: 23546595
    [Abstract] [Full Text] [Related]

  • 17. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR, Postier RG, Li M, Lerner MR, Lightfoot SA, Peyton MD, Deb SJ, Baker CM, Williams TL, Hanas RJ, Stowell DE, Lander TJ, Brackett DJ, Hanas JS.
    Cancer Lett; 2015 Apr 10; 359(2):314-24. PubMed ID: 25637792
    [Abstract] [Full Text] [Related]

  • 18. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S, Taylor WR, Foote PH, Berger CK, Wu CW, Mahoney DW, Bamlet WR, Burger KN, Postier N, de la Fuente J, Doering KA, Lidgard GP, Allawi HT, Petersen GM, Chari ST, Ahlquist DA, Kisiel JB.
    Clin Cancer Res; 2021 May 01; 27(9):2523-2532. PubMed ID: 33593879
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.